21 results on '"Sabins, Nina"'
Search Results
2. Data from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
3. Data from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
4. Supplementary Figure 3 from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
5. Supplementary Figure 2 from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
6. Supplementary Figure 1 from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
7. Supplementary Figure Legends 1-3 from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
8. Supplementary Figure 2 from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
9. Supplementary Figure Legends 1-3 from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
10. Supplementary Figure 3 from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
11. Supplementary Figure 1 from Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
12. A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients With Moderately to Severely Active Crohn’s Disease
13. Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature
14. TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1
15. Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice
16. Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4+ and CD8+ T Cells
17. TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway
18. Therapeutic vaccination against tumor pericyte-associated antigens DLK1 and DLK2 (VAC12P.1013)
19. DLK1: A Novel Target for Immunotherapeutic Remodeling of the Tumor Blood Vasculature
20. Vaccination against DLK-1 and DLK-2 as a cancer therapy (P4306)
21. Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.